HIV, Gilead
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
1d
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure ...
| Dr. Buzón discusses bridging science and reality, highlighting the vital role of real-world evidence in advancing HIV care ...
News Medical on MSN18h
HPTN 094 study examines a novel way to take addiction care and HIV prevention to people who inject drugsResearchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 (“INTEGRA”) study at the 2025 ...
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback